Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · May 2019
Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Global targets to eliminate hepatitis C (HCV) might be met by sustained treatment uptake. ⋯ Broad treatment access led to rapid initial increases in treatment uptake, but this uptake has not been sustained. Our results suggest achieving global elimination targets requires more than treatment availability: people with HCV need easy access to testing and linkage to care in community settings employing a diverse prescriber base.
-
Aliment. Pharmacol. Ther. · Apr 2019
Clinical TrialA prospective study of the incidence of drug-induced liver injury by the modern volatile anaesthetics sevoflurane and desflurane.
Volatile anaesthetics are known to cause drug-induced liver injury, a hepatotoxic reaction characterised by antibodies to trifluoroacetylated lipid and protein adducts and cytochrome p450 2E1. The incidence of volatile anaesthetic drug-induced liver injury from older agents has been described, but modern agents have not been prospectively studied. ⋯ Volatile anaesthetic drug-induced liver injury from modern agents seems to be as common (4.1%) as previously reported with older agents (3%), and may identify patients at risk of severe acute liver injury with subsequent re-exposure.